Term

Count

%

P-Value

Pathways in cancer

34

65.4

2.9E−27

Lipid and atherosclerosis

23

44.2

5.4E−22

AGE-RAGE signaling pathway in diabetic complications

18

34.6

8.8E−21

Human cytomegalovirus infection

22

42.3

4.2E−20

Kaposi sarcoma-associated herpesvirus infection

21

40.4

5.5E−20

Bladder cancer

14

26.9

7E−20

Proteoglycans in cancer

21

40.4

1.7E−19

Fluid shear stress and atherosclerosis

18

34.6

3.1E−18

IL-17 signaling pathway

16

30.8

6.4E−18

Hepatitis B

18

34.6

4.3E−17

Chemical carcinogenesis-receptor activation

19

36.5

2E−16

Endocrine resistance

15

28.8

4.7E−16

HIF-1 signaling pathway

15

28.8

2.3E−15

PI3K-Akt signaling pathway

21

40.4

8.3E−15

Hepatitis C

16

30.8

1.8E−14

Chagas disease

14

26.9

2.9E−14

C-type lectin receptor signaling pathway

14

26.9

3.7E−14

Influenza A

16

30.8

6.4E−14

Measles

15

28.8

7.3E−14

TNF signaling pathway

14

26.9

1E−13

Prostate cancer

13

25

4.6E−13

Pancreatic cancer

12

23.1

8.1E−13

EGFR tyrosine kinase inhibitor resistance

12

23.1

1.3E−12

Apoptosis

14

26.9

1.3E−12

Yersinia infection

14

26.9

1.4E−12

Th17 cell differentiation

13

25

1.7E−12

Non-alcoholic fatty liver disease

14

26.9

6.9E−12

Epstein-Barr virus infection

15

28.8

1.3E−11

MAPK signaling pathway

17

32.7

1.3E−11

Relaxin signaling pathway

13

25

1.5E−11

Salmonella infection

16

30.8

1.6E−11

Pertussis

11

21.2

2.7E−11

T cell receptor signaling pathway

12

23.1

2.8E−11

Leishmaniasis

11

21.2

3E−11

Estrogen signaling pathway

13

25

3.3E−11

Human T-cell leukemia virus 1 infection

15

28.8

4.6E−11

Toxoplasmosis

12

23.1

6.3E−11

Breast cancer

13

25

6.9E−11

Colorectal cancer

11

21.2

9.4E−11

Pathogenic Escherichia coli infection

14

26.9

1.5E−10

Thyroid hormone signaling pathway

12

23.1

1.5E−10

Inflammatory bowel disease

10

19.2

1.8E−10

Shigellosis

15

28.8

1.9E−10

Prolactin signaling pathway

10

19.2

3.6E−10

Non-small cell lung cancer

10

19.2

4.6E−10

Platinum drug resistance

10

19.2

5.2E−10

Toll-like receptor signaling pathway

11

21.2

6.4E−10